This opportunity is currently closed.
Sign up for Content Alerts to stay informed when this or related funding opportunities are posted.
2022 SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship (worldwide)
The 2022 SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship from the Society for Immunotherapy of Cancer (SITC) with funding from Mallinckrodt Pharmaceuticals, supports a postdoctoral researcher, resident, research scientist, or comparable position, working on adverse events in cancer immunotherapy. Applicants must be a member of the SITC and hold an MD or MD/PhD degree. Applications are open to candidates worldwide. The fellowship provides funding of 40,000 USD over 1 year plus financial support to attend SITC´s 37th Annual Meeting. Applications close on April 5, 2022.
Create or sign in to your free account for more functionalities, including a full display of the eligibility criteria such as location and citizenship requirements.